Myriad Genetics Shares Outstanding History (MYGN)
Myriad Genetics reported 93.5M shares outstanding at the end of fiscal 2025.
View full Myriad Genetics company overviewMyriad Genetics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 93.5M | 2.2M | +2.41% |
| 2024 | 2024-12-31 | 91.3M | 1.4M | +1.56% |
| 2023 | 2023-12-31 | 89.9M | 8.7M | +10.71% |
| 2022 | 2022-12-31 | 81.2M | 1.2M | +1.50% |
| 2021 | 2021-12-31 | 80.0M | 4.6M | +6.10% |
| 2020 · Dec 31 | 2020-12-31 | 75.4M | 700,000 | +0.94% |
| 2020 · Jun 30 | 2020-06-30 | 74.7M | 1.2M | +1.63% |
| 2019 | 2019-06-30 | 73.5M | 2.9M | +4.11% |
| 2018 | 2018-06-30 | 70.6M | 2.2M | +3.22% |
| 2017 | 2017-06-30 | 68.4M | −700,000 | −1.01% |
| 2016 | 2016-06-30 | 69.1M | 200,000 | +0.29% |
| 2015 | 2015-06-30 | 68.9M | −4.6M | −6.26% |
| 2014 | 2014-06-30 | 73.5M | −7.1M | −8.81% |
| 2013 | 2013-06-30 | 80.6M | −2.0M | −2.42% |
| 2012 | 2012-06-30 | 82.6M | −3.6M | −4.23% |
| 2011 | 2011-06-30 | 86.2M | −7.8M | −8.30% |
| 2010 | 2010-06-30 | 94.0M | — | — |
Myriad Genetics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 95.6M | 2.5M | +2.69% |
| Q1 2026 | 2026-03-31 | 94.4M | 2.2M | +2.39% |
| Q4 2025 | 2025-12-31 | 93.5M | 2.2M | +2.41% |
| Q3 2025 | 2025-09-30 | 93.1M | 2.1M | +2.31% |
| Q2 2025 | 2025-06-30 | 93.1M | 2.2M | +2.42% |
| Q1 2025 | 2025-03-31 | 92.2M | 1.7M | +1.88% |
| Q4 2024 | 2024-12-31 | 91.3M | 1.4M | +1.56% |
| Q3 2024 | 2024-09-30 | 91.0M | 8.9M | +10.84% |
| Q2 2024 | 2024-06-30 | 90.9M | 9.0M | +10.99% |
| Q1 2024 | 2024-03-31 | 90.5M | 9.0M | +11.04% |
| Q4 2023 | 2023-12-31 | 89.9M | 8.7M | +10.71% |
| Q3 2023 | 2023-09-30 | 82.1M | 1.2M | +1.48% |
| Q2 2023 | 2023-06-30 | 81.9M | 1.3M | +1.61% |
| Q1 2023 | 2023-03-31 | 81.5M | 1.2M | +1.49% |
| Q4 2022 | 2022-12-31 | 81.2M | 1.2M | +1.50% |
| Q3 2022 | 2022-09-30 | 80.9M | 1.2M | +1.51% |
| Q2 2022 | 2022-06-30 | 80.6M | 2.9M | +3.73% |
| Q1 2022 | 2022-03-31 | 80.3M | 3.6M | +4.69% |
| Q4 2021 | 2021-12-31 | 80.0M | 4.6M | +6.10% |
| Q3 2021 | 2021-09-30 | 79.7M | 4.5M | +5.98% |
| Q2 2021 | 2021-06-30 | 77.7M | 3.0M | +4.02% |
| Q1 2021 · Mar 31 | 2021-03-31 | 76.7M | 2.2M | +2.95% |
| Q4 2020 · Dec 31 | 2020-12-31 | 75.4M | 900,000 | +1.21% |
| Q1 2021 · Sep 30 | 2020-09-30 | 75.2M | 800,000 | +1.08% |
| Q4 2020 · Jun 30 | 2020-06-30 | 74.7M | 1.2M | +1.63% |
| Q3 2020 | 2020-03-31 | 74.5M | 1.1M | +1.50% |
| Q2 2020 | 2019-12-31 | 74.5M | 1.3M | +1.78% |
| Q1 2020 | 2019-09-30 | 74.4M | −300,000 | −0.40% |
| Q4 2019 | 2019-06-30 | 73.5M | 2.9M | +4.11% |
| Q3 2019 | 2019-03-31 | 73.4M | 3.5M | +5.01% |
| Q2 2019 | 2018-12-31 | 73.2M | 3.8M | +5.48% |
| Q1 2019 | 2018-09-30 | 74.7M | 5.5M | +7.95% |
| Q4 2018 | 2018-06-30 | 70.6M | 2.2M | +3.22% |
| Q3 2018 | 2018-03-31 | 69.9M | 1.8M | +2.64% |
| Q2 2018 | 2017-12-31 | 69.4M | 1.3M | +1.91% |
| Q1 2018 | 2017-09-30 | 69.2M | 800,000 | +1.17% |
| Q4 2017 | 2017-06-30 | 68.4M | −700,000 | −1.01% |
| Q3 2017 | 2017-03-31 | 68.1M | −2.3M | −3.27% |
| Q2 2017 | 2016-12-31 | 68.1M | −3.5M | −4.89% |
| Q1 2017 | 2016-09-30 | 68.4M | −1.0M | −1.44% |
| Q4 2016 | 2016-06-30 | 69.1M | 200,000 | +0.29% |
| Q3 2016 | 2016-03-31 | 70.4M | 378,000 | +0.54% |
| Q2 2016 | 2015-12-31 | 71.6M | 82,000 | +0.11% |
| Q1 2016 | 2015-09-30 | 69.4M | −3.6M | −4.91% |
| Q4 2015 | 2015-06-30 | 68.9M | −4.6M | −6.25% |
| Q3 2015 | 2015-03-31 | 70.0M | −4.5M | −6.03% |
| Q2 2015 | 2014-12-31 | 71.5M | −2.5M | −3.32% |
| Q1 2015 | 2014-09-30 | 73.0M | −3.8M | −4.99% |
| Q4 2014 | 2014-06-30 | 73.5M | −7.1M | −8.79% |
| Q3 2014 | 2014-03-31 | 74.5M | −5.3M | −6.64% |
| Q2 2014 | 2013-12-31 | 74.0M | −7.3M | −9.02% |
| Q1 2014 | 2013-09-30 | 76.8M | −4.6M | −5.63% |
| Q4 2013 | 2013-06-30 | 80.6M | −2.0M | −2.41% |
| Q3 2013 | 2013-03-31 | 79.8M | −4.7M | −5.59% |
| Q2 2013 | 2012-12-31 | 81.3M | −2.9M | −3.47% |
| Q1 2013 | 2012-09-30 | 81.4M | −3.2M | −3.82% |
| Q4 2012 | 2012-06-30 | 82.6M | −3.7M | −4.26% |
| Q3 2012 | 2012-03-31 | 84.5M | −1.2M | −1.37% |
| Q2 2012 | 2011-12-31 | 84.2M | −5.9M | −6.55% |
| Q1 2012 | 2011-09-30 | 84.6M | −7.7M | −8.36% |
| Q4 2011 | 2011-06-30 | 86.2M | −7.8M | −8.30% |
| Q3 2011 | 2011-03-31 | 85.7M | — | — |
| Q2 2011 | 2010-12-31 | 90.1M | — | — |
| Q1 2011 | 2010-09-30 | 92.4M | — | — |
| Q4 2010 | 2010-06-30 | 94.0M | — | — |
Myriad Genetics shares outstanding trends
Over the last five reported fiscal years, Myriad Genetics's shares outstanding moved from 75.4M to 93.5M, a change of 18.1M. The latest reported quarter, Q2 2026, shows 95.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Myriad Genetics filings at SEC.gov ↗